Genetic Engineering & Biotechnology News

SEP1 2016

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/716943

Contents of this Issue

Navigation

Page 33 of 45

32 | SEPTEMBER 1, 2016 | GENengnews.com | Genetic Engineering & Biotechnology News help clinicians work in accordance with the latest genomic knowledge. One such inter- mediary is the Clinical Pharmacogenetics Implementation Consortium (CPIC), an or- ganization working to streamline the process of translating genetic test results into gene- based prescription recommendations. "The goal of the CPIC is to facilitate the process to apply pharmacogenetics to clini- cal practice by developing guidelines for cli- nicians," states Kelly E. Caudle, Pharm.D., Ph.D., CPIC coordinator, St. Jude Children's Research Hospital. "We do not tell clini- cians if genetics testing should be ordered, but rather what to do with the information when it is available." The CPIC strives to provide clear, concise information for pro- viders, explaining how genetic data applies to their patients. "A genetic test is unlike a blood glucose test, which is merely a snapshot of a dynamic situation," Dr. Caudle continues. "Genetic results follow a patient for a lifetime." Hence, genetic information needs to be entered into a patient's electronic health record (EHR) in a time-independent way. When a physician orders a drug for a patient 15 years after the genetic test was added, an alert needs to in- form the clinician about the results of genet- ics testing in relation to the treatment. Pharmacogenetics Informs Clinical Practice TRANSLATIONAL MEDICINE Continued from page 1 The CYP2D6 gene, depicted at the top of this image as a series of numbered black boxes (exons), codes for an enzyme that metabolizes a quarter of all prescribed drugs. Below this graphic are individual single-molecule real-time (SMRT) sequencing reads, each about 5 kilobases in length, for five unidentified patient samples. These reads, obtained via Pacific Biosciences technology, show that CYP2D6 variants are widespread. Green: adenine; orange: guanine; blue: cytosine; red: thymine. Enlarged section: heterozygous guanine/cytosine variant, with its accompanying SMRT sequencing reads. Image courtesy of Stuart A. Scott, Ph.D., and Yao Yang, Ph.D., of the Icahn School of Medicine at Mount Sinai. STRUCTURAL BIOLOGY SERVICES CONTACT A CAYMAN SCIENTIST TODAY www.caymanchem.com contractresearch@caymanchem.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP1 2016